Christopher I. Li
Ph.D., University of Washington, Epidemiology, 2002.
M.P.H., University of Washington, Epidemiology, 2000.
M.D., University of California, San Francisco, 2000.
B.S., Stanford University, Biological Sciences, 1995.
My research interests lie principally in the field of breast cancer and understanding factors related to its etiology and outcomes using a multidisciplinary approach. I am actively investigating the relationships between various hormonal exposures and risks of different types of breast cancer based on their morphology and expression of different tumor markers. I am also interested in breast cancer outcomes and am currently leading studies that investigate risk factors for second primary breast cancer among breast cancer survivors. Another part of my work focuses on identifying markers that could be used for the early detection of different cancers using various proteomic platforms. Finally, I have an interest in examining disparities in cancer stage, treatment, and survival by race/ethnicity.
(Reading, Writing, Speaking)
Spanish: (Basic, Basic, Basic)
American Association for Cancer Research
2006-2010, Associate Member, Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Program in Epidemiology
Fatal breast cancer risk in relation to use of unopposed estrogen and combined hormone therapy.. Breast cancer research and treatment.. 2014.
Oral contraceptives and breast cancer risk overall and by molecular subtype among young women.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2014.
Dermcidin expression is associated with disease progression and survival among breast cancer patients.. Breast cancer research and treatment.. 2014.
Net risk reclassification p values: valid or misleading? Journal of the National Cancer Institute. 106(4):dju041.. 2014.
Obstetric outcomes in young women with breast cancer: prior, concurrent, and subsequent pregnancies. American Journal of Obstetrics and Gynecology. 210:S313-S313.. 2014.
Long-Term Statin Use and Risk of Ductal and Lobular Breast Cancer among Women 55 to 74 Years of Age.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 22(9):1529-37.. 2013.
AACR Cancer Progress Report 2013.. Clinical cancer research : an official journal of the American Association for Cancer Research. 19(20 Suppl):S1-S98.. 2013.
Reproductive factors and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast cancer among women 20-44 years of age.. Breast cancer research and treatment. 137(2):579-87.. 2013.
Racial/Ethnic Differences in Use and Duration of Adjuvant Hormonal Therapy for Breast Cancer in the Women's Health Initiative.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.. 2013.
Evaluation of seasonality in the diagnosis of acute myeloid leukaemia among adults in the United States, 1992-2008.. British journal of haematology. 160(3):343-50.. 2013.
Use of antihypertensive medications and breast cancer risk.. Cancer causes & control : CCC. 24(2):365-71.. 2013.
Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.. Breast cancer research and treatment. 142(3):629-36.. 2013.
Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years.. JAMA internal medicine.. 2013.
Disparities in Access to Lung Transplantation for Cystic Fibrosis Patients by Socioeconomic Status.. American journal of respiratory and critical care medicine.. 2012.
Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.. Breast cancer research and treatment. 135(2):611-8.. 2012.
Temporal trends in incidence and mortality rates for colorectal cancer by tumor location: 1975-2007.. American journal of public health. 102(9):1791-7.. 2012.
Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.. Breast cancer research and treatment. 135(3):849-55.. 2012.
Breast Density, Body Mass Index, and Risk of Tumor Marker-Defined Subtypes of Breast Cancer.. Annals of epidemiology. 22(5):340-348.. 2012.
Evaluation of Known Oncoantibodies, HER2, p53, and Cyclin B1, in Prediagnostic Breast Cancer Sera.. Cancer prevention research (Philadelphia, Pa.).. 2012.
Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer.. Breast cancer research and treatment. 131(2):607-17.. 2012.